Clinical Trial Update: Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

Phase II study evaluating orelabrutinib in combination with a PD-1 inhibitor for relapsed/refractory primary CNS lymphoma is in progress with status not specifi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: UNKNOWN